Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: Interim results of a phase II prospective study

S. J. Kim, K. Kim, Byung Soo Kim, C. Suh, J. Huh, Y. H. Ko, W. S. Kim

Research output: Contribution to journalArticle

25 Citations (Scopus)
Original languageEnglish
Pages (from-to)390-392
Number of pages3
JournalAnnals of Oncology
Volume20
Issue number2
DOIs
Publication statusPublished - 2009 Feb 25

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this